Towards personalized therapy for patients with glioblastoma.

Abstract:

:Combined therapy with temozolomide and radiotherapy is a standard treatment and improves the survival for patients with newly diagnosed glioblastoma. However, the prognosis remains poor, with a median survival time of 12-15 months. Currently, several clinical trials of dose-dense temozolomide regimen or molecular-targeting therapies have been performed to overcome the resistance of glioblastoma. In these therapies, rational prognostic biomarkers have also been investigated to predict their outcome and response to treatment. This advanced understanding of the biological markers can help to develop personalized therapies for glioblastoma patients. Generally, due to a reduced tolerance, elderly patients do not seem to benefit from intensive treatment. This population needs individual treatments depended on their age or performance status. In this article, we review the recent studies that can provide personalized therapy for glioblastoma, based on molecular tumor profiling or patients' physical status.

authors

Shirai K,Chakravarti A

doi

10.1586/era.11.103

subject

Has Abstract

pub_date

2011-12-01 00:00:00

pages

1935-44

issue

12

eissn

1473-7140

issn

1744-8328

journal_volume

11

pub_type

杂志文章,评审
  • Breath testing as a method for detecting lung cancer.

    abstract::Early diagnosis of lung cancer is important due to high mortality in late stages of the disease. An ideal approach for population screening could be the breath analysis, due to its non-invasiveness, simplicity and cheapness. Using sensitive methods of analysis like gas chromatography/mass spectrometry in exhaled air o...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.2014.866044

    authors: Taivans I,Bukovskis M,Strazda G,Jurka N

    更新日期:2013-12-13 00:00:00

  • Sentinel lymph node biopsy for melanoma of the head and neck.

    abstract::Since its first description nearly two centuries ago, melanoma has been a difficult disease to diagnose and treat. With the incidence and mortality rates slowly increasing, understanding this disease is more important than ever. Herein, the current diagnostic and treatment recommendations for melanoma of the head and ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.3.5.673

    authors: Lentsch EJ,McMasters KM

    更新日期:2003-10-01 00:00:00

  • Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma.

    abstract::According to computed tomography image analysis, skeletal muscle (SM) and adipose tissue areas vary widely in patients with the same body mass index or the same body surface area. Body composition variables such as SM mass, SM density and subcutaneous and visceral adipose tissue have shown value as potential independe...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.866040

    authors: Antoun S,Lanoy E,Albiges-Sauvin L,Escudier B

    更新日期:2014-03-01 00:00:00

  • An evidence-based analysis of the management of N0 neck in patients with cancer of the parotid gland.

    abstract::Introduction: Management of clinically negative neck (cN0) in patients with parotid gland cancer is controversial. Treatment options can include observation, elective neck dissection or elective radiotherapy. Areas covered: We addressed the treatment options for cN0 patients with parotid gland cancer. A literature rev...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2019.1674143

    authors: Vartanian JG,Gonçalves Filho J,Kowalski LP,Shah JP,Suárez C,Rinaldo A,De Bree R,Rodrigo JP,Hamoir M,Takes RP,Mäkitie AA,Zbären P,Andreasen S,Poorten VV,Sanabria A,Hellquist H,Robbins KT,Bödeker CC,Silver C,Ferlito A

    更新日期:2019-10-01 00:00:00

  • Epratuzumab in the therapy of oncological and immunological diseases.

    abstract::B cells play an important role in the pathogenesis of certain lymphomas and leukemias, as well as many autoimmune diseases. Antagonistic B-cell antibodies are thus gaining an increasing role in the management of these diseases. The first antibody target in this regard was CD20, with the development and introduction of...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.10.1341

    authors: Goldenberg DM

    更新日期:2006-10-01 00:00:00

  • Clinical and epidemiologic burden of chronic myelogenous leukemia.

    abstract::Chronic myelogenous leukemia represents 7-20% of all leukemia cases, with a worldwide incidence projected at less than one to two per 100,000 people. Approximately 85% of patients are diagnosed with chronic-phase chronic myelogenous leukemia and up to 40% are asymptomatic. Treatment strategies include chemotherapy, in...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.4.1.85

    authors: Redaelli A,Bell C,Casagrande J,Stephens J,Botteman M,Laskin B,Pashos C

    更新日期:2004-02-01 00:00:00

  • Antiangiogenic therapies: is VEGF-A inhibition alone enough?

    abstract::Although available targeted therapies provide some clinical efficacy, a need remains for antiangiogenic therapies with alternative mechanisms in order to provide better outcomes and the ability to circumvent resistance. Inhibition of multiple VEGF targets may produce enhanced efficacy and more durable responses throug...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/era.11.5

    authors: Gordon MS

    更新日期:2011-03-01 00:00:00

  • Current surgical treatment of intermediate risk differentiated thyroid cancer: a systematic review.

    abstract::Introduction: Surgical treatment of thyroid cancer has become less aggressive but for many patients, the threshold for performing total thyroidectomy (TT), as opposed to thyroid lobectomy (TL), has remained unclear. Current American Thyroid Association (ATA) guidelines encourage more individualization of treatment opt...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1850280

    authors: Guo MY,Wiseman JJ,Wiseman SM

    更新日期:2020-12-15 00:00:00

  • Surgical management of bladder cancer in 2003.

    abstract::Recent advances in molecular and cell biology have led to a greater understanding of the basic biology of bladder cancer. However, despite these advances, surgery remains a key component of modern bladder cancer treatment. Endoscopy is the mainstay of the diagnosis and treatment of superficial bladder cancer. Adjuvant...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.3.6.781

    authors: Wade M,Seigne JD

    更新日期:2003-12-01 00:00:00

  • Oncolytic viruses: a novel form of immunotherapy.

    abstract::Oncolytic viruses are novel anticancer agents, currently under investigation in Phase I-III clinical trials. Until recently, most studies have focused on the direct antitumor properties of these viruses, although there is now an increasing body of evidence that the host immune response may be critical to the efficacy ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.10.1581

    authors: Prestwich RJ,Harrington KJ,Pandha HS,Vile RG,Melcher AA,Errington F

    更新日期:2008-10-01 00:00:00

  • Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years.

    abstract:INTRODUCTION:Myelodysplastic syndromes (MDS) represent a range of bone marrow disorders, with patients affected by cytopenias and risk of progression to AML. There are limited therapeutic options available for patients, including hypomethylating agents (azacitidine/decitabine), growth factor support, lenalidomide, and ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2020.1770088

    authors: Feld J,Belasen A,Navada SC

    更新日期:2020-06-01 00:00:00

  • Emerging personalized approaches for the management of advanced urothelial carcinoma.

    abstract::Urothelial carcinoma of the bladder comprises a spectrum of illnesses ranging from nonmuscle-invasive to muscle-invasive to advanced/metastatic disease. Each of these clinical states is characterized by a unique pathogenesis, prognosis and approach to treatment. However, given the heterogeneity of urothelial carcinoma...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.141

    authors: Tsao CK,Gartrell BA,Oh WK,Galsky MD

    更新日期:2012-12-01 00:00:00

  • Lymphocele: prevalence and management in gynecological malignancies.

    abstract::A lymphocele is a cystic mass that may occur in the retroperitoneum following a systematic pelvic and/or para-aortic lymphadenectomy. Lymphoceles may be the cause of severe morbidity, or rarely mortality. Symptomatic lymphoceles manifest with pain, compression of adjacent structures, lymphoedema, deep vein thrombosis ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.866043

    authors: Weinberger V,Cibula D,Zikan M

    更新日期:2014-03-01 00:00:00

  • Therapeutic approaches for refractory germ cell cancer.

    abstract:INTRODUCTION:Most germ cell cancer patients with metastatic disease are cured by cisplatin-based combination chemotherapy. 30% of metastatic patients will develop relapse or progress despite adequate first-line treatment and will require salvage therapy, with about 10% of metastasized patients ultimately developing pla...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1450630

    authors: Oing C,Seidel C,Bokemeyer C

    更新日期:2018-04-01 00:00:00

  • Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options.

    abstract:INTRODUCTION:Adrenocortical carcinoma (ACC) is a rare tumor characterized by poor prognosis in most cases. Moreover, in most cases ACC produces an excess of adrenal steroid hormones with relevant clinical consequences. Areas covered: After an extensive literature search, this narrative review addresses diagnostic manag...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1510325

    authors: Puglisi S,Perotti P,Cosentini D,Roca E,Basile V,Berruti A,Terzolo M

    更新日期:2018-11-01 00:00:00

  • Notch signaling in lung cancer.

    abstract::Lung cancer is the leading cause of cancer-related deaths in the Western world. The lungs can be affected by a number of histologically diverse malignancies. Nonetheless, the vast majority of lung cancers are classified as non-small-cell lung cancer (NSCLC). Despite extensive research on different therapeutic regimens...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.158

    authors: Galluzzo P,Bocchetta M

    更新日期:2011-04-01 00:00:00

  • Developments in predictive biomarkers for hepatocellular carcinoma therapy.

    abstract::Introduction: Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and the third largest cause of cancer-relateddeaths worldwide. Potentially curative treatments (surgical resection, radiofrequency or liver transplantation) are only available for few patients, while transarterial chemoembolizat...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2020.1712198

    authors: Casadei-Gardini A,Orsi G,Caputo F,Ercolani G

    更新日期:2020-01-01 00:00:00

  • Organ preservation strategies in bladder cancer.

    abstract::Bladder cancer is a significant cause of morbidity and mortality. Promising results with organ preservation strategies using multimodality treatment over the last decade offers an option for bladder preservation in a significant proportion of patients who currently undergo cystectomy. The primary goal of the bladder-s...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2.6.641

    authors: Hussain SA,James ND

    更新日期:2002-12-01 00:00:00

  • Advances in the treatment of Waldenström's macroglobulinemia.

    abstract::Waldenström's macroglobulinemia is a distinct disorder characterized by a monoclonal immunoglobulin M paraprotein and morphological evidence of lymphoplasmacytic lymphoma. It is relatively rare, accounting for approximately 2% of all hematological malignancies. The aim of treatment for patients with Waldenström's macr...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.3.329

    authors: Johnson SA

    更新日期:2006-03-01 00:00:00

  • Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities.

    abstract:INTRODUCTION:Cancer genome sequencing studies have discovered mutations in members of the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin-remodeling complex in nearly 25% of human cancers. The SWI/SNF complex, first discovered in S. cerevisiae, shows strong conservation from yeast to Drosophila to mammals, contains ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2019.1605905

    authors: Orlando KA,Nguyen V,Raab JR,Walhart T,Weissman BE

    更新日期:2019-05-01 00:00:00

  • Timing for starting second-line therapy in recurrent ovarian cancer.

    abstract::Ovarian cancer is the leading cause of gynecologic cancer-related death in Europe and the USA. The optimal treatment strategy for this malignancy includes accurate presurgical and surgical staging, optimal debulking surgery, and first-line therapy with platinum-based chemotherapy. Unfortunately, the majority of patien...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.204

    authors: Guarneri V,Barbieri E,Dieci MV,Piacentini F,Conte P

    更新日期:2011-01-01 00:00:00

  • TIM-3 pathway dysregulation and targeting in cancer.

    abstract:INTRODUCTION:Dysfunction of the immune system is a hallmark of cancer. Through increased understanding of the complex interactions between immunity and cancer, immunotherapy has emerged as a treatment modality for different types of cancer. Promising activity with immunotherapy has been reported in numerous malignancie...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1865814

    authors: Zeidan AM,Komrokji RS,Brunner AM

    更新日期:2021-01-19 00:00:00

  • Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.

    abstract::Until now, no effective systemic treatment options have been available for patients with unresectable advanced hepatocellular carcinoma (HCC). In the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP), patients with unresectable advanced HCC with Child-Pugh liver function class A and who had not...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/era.09.41

    authors: Rimassa L,Santoro A

    更新日期:2009-06-01 00:00:00

  • Screening for ovarian cancer.

    abstract::Ovarian cancer frequently presents late, when chances for long-term survival are poor. The increased survival advantage for patients diagnosed with early-stage ovarian cancer suggests that screening to detect early-stage disease might have an impact on disease mortality. Attempts are being made to develop effective sc...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.3.1.55

    authors: Lewis S,Menon U

    更新日期:2003-02-01 00:00:00

  • Pancreatic cancer: current standards, working towards a new therapeutic approach.

    abstract::Pancreatic cancer is the fourth leading cause of cancer deaths with a 5-year survival of 4-6%. Clinical challenges remain to be addressed, since few promising approaches to treat pancreatic cancer have been reported. Here we discuss the potential of a new biotherapeutic agent composed of a lysosomal protein (Saposin C...

    journal_title:Expert review of anticancer therapy

    pub_type: 社论

    doi:10.1586/14737140.2014.895937

    authors: Olowokure O,Qi X

    更新日期:2014-05-01 00:00:00

  • Emerging application of stereotactic body radiation therapy for gynecologic malignancies.

    abstract::Stereotactic body radiation therapy (SBRT) involves delivery of image-guided, ablative radiation doses to planning treatment volume(s) using sophisticated dosimetric planning and target localization. Early on, clinical investigators pursued SBRT for the treatment of early stage non-small-cell lung cancer, lung and liv...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.81

    authors: Mayr NA,Huang Z,Sohn JW,Lo SS,Teh BS,Lu JJ,Grecula JC,Kunos C

    更新日期:2011-07-01 00:00:00

  • Response to systemic therapy in locally advanced and metastatic renal cell carcinoma: can it be predicted?

    abstract:INTRODUCTION:: Renal cell carcinoma is no longer considered a monolithic disease, but a group of different entities exhibiting unique molecular alterations requiring a tailored systemic approach. One of the remaining challenges is the identification of the best candidate for a particular therapeutic regimen. AREAS COV...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1878882

    authors: González J,Gaynor JJ,Ciancio G

    更新日期:2021-01-29 00:00:00

  • New drug therapies for advanced renal cell carcinoma.

    abstract::The incidence of renal cell cancer is increasing and surgery is the only curative treatment for patients presenting with localized disease at diagnosis. The treatment of metastatic renal cell cancer is palliative and, until recently, immunotherapy has been the standard treatment approach with response rates between 10...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.1.57

    authors: Gore ME,Harrison ML,Montes A

    更新日期:2007-01-01 00:00:00

  • Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.

    abstract::Immunotherapies such as sipuleucel-T present new and unique challenges for the optimal timing and sequencing of therapies for metastatic castration-resistant prostate cancer (mCRPC). Key considerations for the sequencing of sipuleucel-T are its unique proposed mechanism of action, the time required to generate a clini...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.848065

    authors: Quinn DI,Vaishampayan U,Higano CS,Lin DW,Shore ND,Beer TM

    更新日期:2014-01-01 00:00:00

  • Metastatic soft tissue sarcoma: current treatment landscape and future perspectives.

    abstract:INTRODUCTION:The therapeutic armamentarium for advanced soft tissue sarcoma (STS) has increased over the last few years. Doxorubicin monotherapy or in combination is now the established first line treatment. Beyond first line treatment, no standard therapy has been established. Novel drugs have reached the late-clinica...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2017.1321989

    authors: Skafida E,Kokkali S,Nikolaou M,Digklia A

    更新日期:2017-06-01 00:00:00